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Purpose of the study
In order to evaluate variables correlated to self-reported
discontinuations (SRDisc) of HAART in HIV-infected peo-
ple, a prospective, cohort(AdUCSC), monocenter study
was conducted.
Methods
A short questionnaire on adherence (0 to 100 scale on the
question "How much are you adherent to drug prescrip-
tions?"), self-reported discontinuations, satisfaction and
trust in therapy, physical (PhysH) and Mental(MentH)
Health, and self-reported symptoms was administered at
any visit to any outpatient taking HAART. An automatic
report resuming the adherence, self-reported discontinua-
tions and health status measures was generated and sent
to physician for discussion with patient at the following
visit. A SRDisc event was defined when patient reported
having stopped all the drugs for at least 24 hours in the 2
months before. A composite measure for viro-immuno-
logical failure was used (CD4<200 or CD4 decreasing
respect to a 1-year previous value or HIV-RNA>50 c/ml).
A symptom score was built summing self-reported scores
(from 0-at all to 4-very much) for each of 19 listed symp-
toms.
Summary of results
At May 2008, 515 patients had filled the questionnaire:
33% females, mean age 45 years (SD 8.7), IDU 20%,
median of HIV 11 years (IQR 6–15); median log HIV-RNA
1.7 c/ml (IQR 1.7–1.7), median CD4 572/mm3 (IQR
414–778). 54% were taking PI, 30% NNRTI, and 13%
only NRTI; <10% were previously naive to antiretrovirals.
40.6% were taking a QD regimen. Mean SelfAdher was
79.3 (SD 18.5); 19.5% reported adherence<60. 14.5%
reported having missed at least one dose in the previous
week. 119 (23.1%) reported having done at least one 24-
hour of discontinuations in the 2 months before. Risk of
viro-immunological failure was higher for people self-
reporting discontinuation compared to those not (OR
1.85; 95% CI 1.15–2.98; p = 0.01). Self-reporting discon-
tinuations were also correlated to self-reported adherence
(for any point more of adherence OR 0.95; 95% CI 0.94–
0.97; p < 0.001).
At multivariable analysis, even adjusted for type of
HAART, variables independently correlated to self-report-
ing a discontinuation were: being female (OR 1.98; 95%
CI 1.09–3.58; p = 0.02), IDU (OR 2.10; 95% CI 1.07–
4.13; p = 0.03), taking a QD regimen (OR 1.96; 95% CI
1.10–3.48; p = 0.02), and symptom score (OR 1.02; 95%
CI 1.0–1.06; p = 0.05).
Conclusion
Being female, IDU, taking a QD regimen and symptom
score were correlated to self-chosen discontinuations of
HAART. It is possible that people taking a QD regimen
perceive therapy as a very easy task and are more prone to
forgetful events.
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